PharmaShots | Incisive News in 3 Shots

Subscribe Now

MONALEESA-3

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

September 22, 2020

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

August 1, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us